Opus Genetics (IRD) president awarded 400,000 RSUs vesting over 16 quarters

Rhea-AI Filing Summary

Opus Genetics, Inc. President and director Benjamin R. Yerxa reported an equity award in the form of 400,000 shares of common stock on January 22, 2026. The filing shows the shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 719,005 shares of common stock directly. According to the footnote, the award represents restricted stock units that vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, conditioned on his continued service.

Insights

Equity compensation and governance analyst

Large time-based stock grant to Opus Genetics president, vesting over four years.

The filing shows that Opus Genetics President and director Benjamin R. Yerxa received a grant of 400,000 restricted stock units of common stock at $0 per share on January 22, 2026. This is reported as a non-derivative acquisition of common stock, bringing his direct beneficial ownership to 719,005 shares after the grant.

The footnote explains that these RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, subject to his continuing service. This structure ties the value of the award to both his tenure and the company’s future share performance, spreading potential dilution over time rather than all at once.

As a routine equity incentive for a senior executive and director, this type of grant is common in public companies. The economic impact depends on future vesting and any subsequent share sales, which would be disclosed in later insider reports if they occur.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YERXA BENJAMIN R

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		400,000(1)	A	$0	719,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

	/s/ Amy Rabourn, by Power of Attorney	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Opus Genetics (IRD) President Benjamin Yerxa report in this Form 4?

The Form 4 reports that Benjamin R. Yerxa, President and director of Opus Genetics, Inc., received an award of 400,000 shares of common stock on January 22, 2026. The shares are shown at a price of $0 per share, indicating an equity grant rather than a market purchase.

How do the 400,000 shares granted to the Opus Genetics president vest?

The filing states that the 400,000 shares represent restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, and vesting is subject to the reporting person’s continuing service.

How many Opus Genetics (IRD) shares does Benjamin Yerxa own after this transaction?

After the reported grant, Benjamin R. Yerxa beneficially owns 719,005 shares of Opus Genetics common stock. The Form 4 identifies this ownership as direct.

Was this Opus Genetics insider transaction a purchase on the open market?

No. The transaction is coded as an acquisition of Common Stock at a price of $0 per share and is described in the footnote as a grant of restricted stock units, not an open-market purchase.

What is the role of the reporting person in Opus Genetics (IRD)?

The reporting person, Benjamin R. Yerxa, is listed as both a director and an officer of Opus Genetics, with the officer title of President.